Literature DB >> 28570818

Chirality Dependent Potency Enhancement and Structural Impact of Glycol Nucleic Acid Modification on siRNA.

Mark K Schlegel1, Donald J Foster1, Alexander V Kel'in1, Ivan Zlatev1, Anna Bisbe1, Muthusamy Jayaraman1, Jeremy G Lackey1, Kallanthottathil G Rajeev1, Klaus Charissé1, Joel Harp2, Pradeep S Pallan2, Martin A Maier1, Martin Egli2, Muthiah Manoharan1.   

Abstract

Here we report the investigation of glycol nucleic acid (GNA), an acyclic nucleic acid analogue, as a modification of siRNA duplexes. We evaluated the impact of (S)- or (R)-GNA nucleotide incorporation on RNA duplex structure by determining three individual crystal structures. These structures indicate that the (S)-nucleotide backbone adopts a conformation that has little impact on the overall duplex structure, while the (R)-nucleotide disrupts the phosphate backbone and hydrogen bonding of an adjacent base pair. In addition, the GNA-T nucleobase adopts a rotated conformation in which the 5-methyl group points into the minor groove, rather than the major groove as in a normal Watson-Crick base pair. This observation of reverse Watson-Crick base pairing is further supported by thermal melting analysis of GNA-C and GNA-G containing duplexes where it was demonstrated that a higher thermal stability was associated with isoguanine and isocytosine base pairing, respectively, over the canonical nucleobases. Furthermore, it was also shown that GNA nucleotide or dinucleotide incorporation increases resistance against snake venom phosphodiesterase. Consistent with the structural data, modification of an siRNA with (S)-GNA resulted in greater in vitro potencies over identical sequences containing (R)-GNA. A walk of (S)-GNA along the guide and passenger strands of a GalNAc conjugate duplex targeting mouse transthyretin (TTR) indicated that GNA is well tolerated in the seed region of both strands in vitro, resulting in an approximate 2-fold improvement in potency. Finally, these conjugate duplexes modified with GNA were capable of maintaining in vivo potency when subcutaneously injected into mice.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28570818     DOI: 10.1021/jacs.7b02694

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  21 in total

Review 1.  Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

Authors:  Alexandre J Debacker; Jon Voutila; Matthew Catley; David Blakey; Nagy Habib
Journal:  Mol Ther       Date:  2020-06-17       Impact factor: 11.454

Review 2.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

3.  Development of siRNA Therapeutics for the Treatment of Liver Diseases.

Authors:  Anja Holm; Marianne Bengtson Løvendorf; Sakari Kauppinen
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Therapeutic RNA-silencing oligonucleotides in metabolic diseases.

Authors:  Algera Goga; Markus Stoffel
Journal:  Nat Rev Drug Discov       Date:  2022-02-24       Impact factor: 84.694

5.  Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity.

Authors:  Ken Yamada; Samuel Hildebrand; Sarah M Davis; Rachael Miller; Faith Conroy; Ellen Sapp; Jillian Caiazzi; Julia F Alterman; Loic Roux; Dimas Echeverria; Matthew R Hassler; Edith L Pfister; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2021-12-02       Impact factor: 16.971

6.  An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis.

Authors:  Batuhan Yenilmez; Nicole Wetoska; Mark Kelly; Dimas Echeverria; Kyounghee Min; Lawrence Lifshitz; Julia F Alterman; Matthew R Hassler; Samuel Hildebrand; Chloe DiMarzio; Nicholas McHugh; Lorenc Vangjeli; Jacquelyn Sousa; Meixia Pan; Xianlin Han; Michael A Brehm; Anastasia Khvorova; Michael P Czech
Journal:  Mol Ther       Date:  2021-11-11       Impact factor: 11.454

7.  Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates.

Authors:  Kirk M Brown; Jayaprakash K Nair; Maja M Janas; Yesseinia I Anglero-Rodriguez; Lan T H Dang; Haiyan Peng; Christopher S Theile; Elena Castellanos-Rizaldos; Christopher Brown; Donald Foster; Jeffrey Kurz; Jeffrey Allen; Rajanikanth Maganti; Jing Li; Shigeo Matsuda; Matthew Stricos; Tyler Chickering; Michelle Jung; Kelly Wassarman; Jeff Rollins; Lauren Woods; Alex Kelin; Dale C Guenther; Melissa W Mobley; John Petrulis; Robin McDougall; Timothy Racie; Jessica Bombardier; Diana Cha; Saket Agarwal; Lei Johnson; Yongfeng Jiang; Scott Lentini; Jason Gilbert; Tuyen Nguyen; Samantha Chigas; Sarah LeBlanc; Urjana Poreci; Anne Kasper; Arlin B Rogers; Saeho Chong; Wendell Davis; Jessica E Sutherland; Adam Castoreno; Stuart Milstein; Mark K Schlegel; Ivan Zlatev; Klaus Charisse; Mark Keating; Muthiah Manoharan; Kevin Fitzgerald; Jing-Tao Wu; Martin A Maier; Vasant Jadhav
Journal:  Nat Biotechnol       Date:  2022-06-02       Impact factor: 68.164

8.  From bench to bedside: Improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization.

Authors:  Mark K Schlegel; Maja M Janas; Yongfeng Jiang; Joseph D Barry; Wendell Davis; Saket Agarwal; Daniel Berman; Christopher R Brown; Adam Castoreno; Sarah LeBlanc; Abigail Liebow; Tara Mayo; Stuart Milstein; Tuyen Nguyen; Svetlana Shulga-Morskaya; Sarah Hyde; Sally Schofield; John Szeto; Lauren Blair Woods; Vedat O Yilmaz; Muthiah Manoharan; Martin Egli; Klaus Charissé; Laura Sepp-Lorenzino; Patrick Haslett; Kevin Fitzgerald; Vasant Jadhav; Martin A Maier
Journal:  Nucleic Acids Res       Date:  2022-06-23       Impact factor: 19.160

9.  Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo.

Authors:  Christian Berk; Gianluca Civenni; Yuluan Wang; Christian Steuer; Carlo V Catapano; Jonathan Hall
Journal:  Nucleic Acid Ther       Date:  2020-04-20       Impact factor: 5.486

10.  Site-specific Incorporation of 2',5'-Linked Nucleic Acids Enhances Therapeutic Profile of Antisense Oligonucleotides.

Authors:  Thazha P Prakash; Jinghua Yu; Wen Shen; Cheryl Li De Hoyos; Andres Berdeja; Hans Gaus; Xue-Hai Liang; Stanley T Crooke; Punit P Seth
Journal:  ACS Med Chem Lett       Date:  2021-04-05       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.